European Society of Cardiology :ESC Bench to Bedside webinar series

 

Issue 3 Dear Ms Chadzidakis Vavouranakis,  We are pleased to share that the latest issue of the ESC Bench to Bedside webinar series is now available. This issue, Amyloidosis, focuses on the evolving management of transthyretin amyloidosis cardiomyopathy (ATTR-CM), from disease biology and emerging therapeutic approaches to the latest clinical trial evidence. Explore the mechanisms behind stabilisers, silencers, antibody therapies and gene editing, review the evidence across therapeutic classes, and consider how to approach treatment sequencing and patient selection in clinical practice. Get started now with issue 3 Register for our upcoming webinars From Science to Trials   7 September 2026 18:00–19:00 CEST Amyloidosis: from protein misfolding to therapy: stabilizers, silencers, antibodies, and gene editing in ATTR Register   From Trials to Results   28 September 2026 18:00–19:00 CEST Amyloidosis : clinical trial evidence across therapeutic classes in ATTR-CM Register      From Results to Patient Care   5 October 2026   18:00–19:00 CEST Amyloidosis : Treatment sequencing and patient selection in the era of multiple ATTR therapies Register       Whatever your career stage, ESC Education supports your continued learning and professional development. Explore our educational programmes and find the knowledge and resources you need, delivered in a range of formats to suit your learning preferences. Your ESC Team   This programme is supported by Alnylam Pharmaceuticals through an independent support grant. The scientific programme has not been influenced in any way by its grant provider.       Our Diversity Is Our Strength   politikimx@gmail.com.   Contact us